Red Dye 3 vs Butylated Hydroxyanisole: which is worse?

What is Red Dye 3?

Red Dye 3 (erythrosine) is a synthetic cherry-pink fluorescent dye belonging to the xanthene class. It contains approximately 58% iodine by weight, distinguishing it from azo dyes. Its chemical formula is C20H6I4Na2O5. Approved since 1907, it is one of the oldest certified US food colorants and was notably the first synthetic food dye formally revoked by the FDA in decades.

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum (see also bha entry). It is a mixture of 2-BHA and 3-BHA isomers, used to prevent oxidative rancidity in fats, oils, and fat-containing foods. Chemical formula C11H16O2.

Documented risks

Red Dye 3: The FDA revoked Red Dye 3 authorization in January 2025, marking the first synthetic food dye ban by the FDA since Red Dye 2 in 1976. The revocation was triggered by the Delaney Clause, which mandates revocation of any food additive found to cause cancer in animals regardless of dose. The carcinogenicity data stems from studies showing that high doses of erythrosine caused thyroid follicular cell tumors in male rats. The mechanism is indirect: erythrosine suppresses thyroid-stimulating hormone (TSH) feedback by elevating thyroxine (T4) levels, causing chronic TSH suppression that promotes thyroid cell proliferation and ultimately tumor formation. This is a rat-specific mechanism related to their thyroxine-binding protein system, which differs from human biology. EFSA's 2011 comprehensive safety assessment concluded erythrosine was unlikely to be genotoxic at typical food use levels and set an ADI of 0.1 mg/kg body weight — one of the lowest for any food color. EFSA restricted EU use to cocktail cherries only (max 200 mg/kg). The high iodine content (58% by weight) raises concerns for thyroid-sensitive individuals. Excessive erythrosine intake could theoretically contribute to iodine overload and thyroid disruption, particularly in individuals with hyperthyroidism or Hashimoto's disease. The FDA had been aware of the rat thyroid tumor data since 1990 but delayed action for 35 years. Advocacy groups including CSPI petitioned for a ban since 1983. The January 2025 revocation finally addressed this long-standing regulatory gap.

Butylated Hydroxyanisole: IARC classifies BHA as Group 2B (possible human carcinogen) based on forestomach tumor studies in rodents at high doses. The NTP lists it as 'reasonably anticipated to be a human carcinogen.' EFSA's 2012 review found endocrine-disrupting potential. Japan banned it for food use. The FDA permits it at 0.02% of fat content. Concerns about estrogen-receptor interaction have been documented in animal studies. Contact dermatitis from cosmetic use is reported.